New
HealthMore in Health→
SGLT2 Inhibitors Show Benefits in Older CKD Patients
Key Takeaways
- Analysis included 10,076 adults aged 80 or older with chronic kidney disease.
- SGLT2 inhibitor initiation was associated with lower all-cause mortality and fewer major adverse kidney events over two years.
- Researchers also reported higher risks of certain cardiac events and acute kidney injury.
DE
DT Editorial Team··via medicalxpress.com